Coming together to fight COVID-19: A conversation with Ramona Sequeira, President of Takeda Pharmaceuticals U.S.A
By Stephen J. Ubl | September 23, 2020
Over the last seven months, our industry has been working around the clock to combat the COVID-19 virus, including developing effective therapeutics to treat COVID-19 and vaccines to prevent...
Read More
Study finds middlemen excluded nearly 850 medicines from formularies this year
By Katie Koziara | September 17, 2020
A new study from Xcenda finds that from 2014 to 2020, the number of medicines excluded by at least one of the three largest pharmacy benefit managers (PBMs) from their standard formularies...
Read More
Coming together to fight COVID-19: A conversation with Albert Bourla, Chairman & CEO of Pfizer, Inc.
By Stephen J. Ubl | September 17, 2020
Over the last seven months, our industry has been working around the clock to combat the COVID-19 virus, including developing potential therapeutics to treat COVID-19 and vaccines to prevent...
Read More
Recent administration actions undermine patient assistance programs
By Nicole Longo | September 16, 2020
While all eyes and ears are focused on COVID-19 and beating this pandemic, the administration has pursued harmful policy changes that we can’t let slip under the radar. In two back-to-back...
Read More
Guest Post: How proactivity and planning helped Novartis ensure a stable supply of medicines during COVID-19
By Guest Contributor | September 16, 2020
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
New Graphic: Public-Private collaboration fuels the U.S. biopharmaceutical ecosystem
By Jocelyn Ulrich | September 16, 2020
America’s biopharmaceutical companies are at the heart of a robust research and development (R&D) ecosystem that develops more innovative medicines than any other country in the world. In recent...
Read More
National Medicare Education Week: The history of Medicare Part D
By Tom Wilbur | September 15, 2020
Today, in honor of National Medicare Education Week, we’ll be taking a quick look back at the history of Medicare, specifically the Medicare Part D prescription drug benefit .
Read More
PhRMA member companies invested $83 billion in research and development last year
By Tim McClung | September 10, 2020
PhRMA member companies invested $83 billion in research and development (R&D) in 2019, the highest level of investment on record, according to the 2020 PhRMA member annual survey. Over the past...
Read More
PhRMA will continue to advocate for equity within our industry
By Yolanda Hutchins | September 10, 2020
When I first started at PhRMA two and a half years ago, our organization was just starting to talk about how we could increase and activate our commitment to diversity & inclusion (D&I). As senior...
Read More
Coming together to fight COVID-19: A conversation with Joaquin Duato, vice chairman of the executive committee at Johnson & Johnson
By Stephen J. Ubl | September 9, 2020
Over the last seven months, our industry has been working around the clock to combat the COVID-19 virus, including developing effective therapeutics to treat COVID-19 and vaccines to prevent...
Read More
Medicare Monday (100)
340B Spotlight (43)
Cost & Consequence (0)
